




I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231 on September 27, 2002

#10
AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Examining Group
Patent Application
Docket No. UF-267XC1
Serial No. 10/080,772


Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645
Applicants : Janet K. Yamamoto, Jennifer White Janelle, Barbara A. Torres, Maki Arai, Taishi Tanabe, Ruiyu Pu
Serial No. : 10/080,772
Filed : February 22, 2002
Conf. No. : 1105
For : Materials and Methods for Detecting, Preventing, and Treating Retroviral Infection

Box SEQUENCE
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825:

In the Specification

Please replace original pages 1-87 (Sequence Listing) with new pages 1-61 attached hereto.